A Phase 3 interventional study of Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) and Ethinyl estradiol, Levonorgestrel (Miranova) in Primary Dysmenorrhea, sponsored by Bayer. Completed at 42 sites in 6 countries. Open to female participants aged 14 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-24.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Dysmenorrhea by Bayer — none open to participants now, none under way, none of them phase 3. Dysmenorrhea · Bayer.
Among the 11 studies in Dysmenorrhea by Bayer, this one is the only one that started in 2009, is one of 4 in phase 3, and was the 4th registered.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
Browse Dysmenorrhea studies →None of the 11 studies in Dysmenorrhea by Bayer is open now. The open studies under Dysmenorrhea, anywhere →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.
This study: 14 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 223 across the 7 interventional studies, 658 across the 4 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Dysmenorrhea by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other methods:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles
Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) · Drug: Placebo Match to SH T00658ID
Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles
Drug: Ethinyl estradiol, Levonorgestrel (Miranova) · Drug: Placebo Match to SH D593B
Drug pages: Estradiol · Dienogest
Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
Drug pages: Ethinyl Estradiol · Levonorgestrel
Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain
Dysmenorrheic pain was defined as pelvic pain during the menstrual/withdrawal bleeding episode and the 2 days before this episode. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain
Dysmenorrheic pain: pelvic pain during menstrual/withdrawal bleeding (WB) episode and 2 days before. Scores per day: 0 No pain; 1 Mild pain with no need for painkiller; 2 Moderate pain with need for painkiller; 3 Severe pain with need for painkiller. Baseline period: 2 days before 1st menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of 1st treatment cycle until 3rd day before WB of the cycle after 2nd treatment cycle (normalized to standard 56-day period). Score difference min -168 (best), max 168 (worst)
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding
Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding
Evaluated was the number of days with bleeding-associated pelvic pain, excluding days during withdrawal bleeding (WB) and the 2 days preceding such WB, and during administration deviation bleeding and the 2 days preceding such bleeding (normalized to a standard 56-day period). Baseline period: 2 days before first menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of the 1st treatment cycle until 3rd day before the WB of the cycle after the 2nd treatment cycle (normalized to standard 56-day period).
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode)
Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used)
Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Only Bleeding Episodes Used Including the Two Days Before)
Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Percentage of Participants With Interference of Dysmenorrheic Pain With Work/School and Social or Other Activity (Entire Evaluation Period Used)
Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
Time frame: baseline period (2 baseline cycles, usually 56 days) vs. treatment period (on-treatment cycles 2 and 3, usually 56 days)
Percentage of Participants Satisfied With Study Treatment
Participants were asked to express the degree of their satisfaction with study treatment.
Time frame: From cycle 1 to cycle 3 (28 days per cycle)
Number of Days With Bleeding or Spotting
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Number of Episodes With Bleeding or Spotting
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Mean Length of Bleeding or Spotting Episodes
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Maximum Length of Bleeding or Spotting Episodes
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Number of Days With Spotting-only
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Number of Episodes With Spotting-only
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Mean Length of Spotting Only Episodes
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Maximum Length of Spotting Only Episodes
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Difference in Duration Between Longest and Shortest Spotting Only Episode
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
Time frame: From day 1 to day 90
Percentage of Participants With Withdrawal Bleeding at Cycle 1
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 1 (28 days per cycle)
Percentage of Participants With Withdrawal Bleeding at Cycle 3
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 3 (28 days per cycle)
Length of Withdrawal Bleeding Episodes at Cycle 1
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 1 (28 days per cycle)
Length of Withdrawal Bleeding Episodes at Cycle 3
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 3 (28 days per cycle)
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.
Time frame: At cycle 1 (28 days per cycle)
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.
Time frame: At cycle 3 (28 days per cycle)
Onset of Withdrawal Bleeding Episodes at Cycle 1
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 1 (28 days per cycle)
Onset of Withdrawal Bleeding Episodes at Cycle 3
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 3 (28 days per cycle)
Percentage of Participants With Intracyclic Bleeding at Cycle 1
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 1 (28 days per cycle)
Percentage of Participants With Intracyclic Bleeding at Cycle 3
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 3 (28 days per cycle)
Number of Intracyclic Bleeding Episodes at Cycle 1
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 1 (28 days per cycle)
Number of Intracyclic Bleeding Episodes at Cycle 3
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 3 (28 days per cycle)
Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 1 (28 days per cycle)
Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
Time frame: At cycle 3 (28 days per cycle)
Number of Intracyclic Bleeding Days at Cycle 1
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.
Time frame: At cycle 1 (28 days per cycle)
Number of Intracyclic Bleeding Days at Cycle 3
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.
Time frame: At cycle 3 (28 days per cycle)
Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.
Time frame: At cycle 1 (28 days per cycle)
Percentage of Participants With Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.
Time frame: At cycle 3 (28 days per cycle)
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Screening
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
Time frame: At screening (28 days)
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Baseline Cycle
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
Time frame: At Baseline (28 days per cycle)
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Cycle 2
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
Time frame: At cycle 2 (28 days per cycle)
Percentage of Participants Missing Time From Work Due to Dysmenorrheic Pain at Final Examination
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
Time frame: At final examination (28 days)
Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of physiotherapy per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of pain medication per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of vitamins per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of massages per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of acupuncture per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of medical counseling per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of alternative medicine per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their own costs of herbs/teas per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire
The participants were asked to complete a resource use questionnaire indicating their other own costs per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
Time frame: At screening (average over 3 months before screening)
Participants With Improvement in the Investigators' Assessment in the Clinical Global Impression
The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Investigators were asked to rate the participants' improvement during the course of the study.
Time frame: At cycle 2 (28 days per cycle)
Participants With Improvement in Participants' Assessment in the Clinical Global Impression
The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Participants were asked to rate their improvement during the course of the study.
Time frame: At cycle 2 (28 days per cycle)
Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: at final examination (28 days)
Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At final examination (28 days)
Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At final examination (28 days)
Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At final examination (28 days)
General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At final examination (28 days)
Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At final examination (28 days)
Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At final examination (28 days)
Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At baseline cycle (28 days per cycle)
Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
Time frame: At final examination (28 days)
Participants aged 14 to 50 years with a need for oral contraception suffering from primary dysmenorrhea were recruited at specialized study sites.
| Milestone | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Started | 253 | 254 |
| Treated | 234 | 230 |
| Completed | 217 | 209 |
| Not completed | 36 | 45 |
| Withdrew: Withdrawal by subject | 6 | 10 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Did not receive study medication | 19 | 24 |
Dysmenorrheic pain was defined as pelvic pain during the menstrual/withdrawal bleeding episode and the 2 days before this episode. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain | -4.6 ± 4.6 | -4.2 ± 4.2 |
Dysmenorrheic pain: pelvic pain during menstrual/withdrawal bleeding (WB) episode and 2 days before. Scores per day: 0 No pain; 1 Mild pain with no need for painkiller; 2 Moderate pain with need for painkiller; 3 Severe pain with need for painkiller. Baseline period: 2 days before 1st menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of 1st treatment cycle until 3rd day before WB of the cycle after 2nd treatment cycle (normalized to standard 56-day period). Score difference min -168 (best), max 168 (worst)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Sum of Score Points of Dysmenorrheic Pain | -10.6 ± 9.7 | -10.0 ± 8.9 |
Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain Independent of Occurrence of Vaginal Bleeding | -4.0 ± 5.7 | -3.7 ± 5.7 |
Evaluated was the number of days with bleeding-associated pelvic pain, excluding days during withdrawal bleeding (WB) and the 2 days preceding such WB, and during administration deviation bleeding and the 2 days preceding such bleeding (normalized to a standard 56-day period). Baseline period: 2 days before first menstrual bleeding until 3rd day before 3rd menstrual bleeding (normalized to standard 56-day period). Treatment period: 2 days before WB of the 1st treatment cycle until 3rd day before the WB of the cycle after the 2nd treatment cycle (normalized to standard 56-day period).
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Change Between Baseline Evaluation Period and Treatment Evaluation Period in Number of Days With Pelvic Pain During Unscheduled Bleeding | 0.3 ± 2.6 | 0.1 ± 2.0 |
Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
| Tablets | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Only Bleeding Episodes Used Including the Two Days Before the Episode) | -6.2 ± 14.8 | -6.6 ± 12.3 |
Rescue medication use was standardized intake of 200 mg Ibuprofen tablets. Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
| Tablets | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Change Between Baseline Evaluation Period and Treatment Evaluation Period in Rescue Medication Use (Entire Evaluation Period Used) | -4.5 ± 19.9 | -5.6 ± 14.3 |
Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
| Percentage of participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Baseline period-daily activities impaired | 92.3 | 91.3 |
| Baseline period- leisure activities impaired | 90.6 | 89.6 |
| Treatment period-daily activities impaired | 51.7 | 56.5 |
| Treatment period- leisure activities impaired | 47.9 | 56.5 |
Interference of dysmenorrheic pain with work/school and social or other activity was assessed (yes/no). Baseline period: 2 days before the first menstrual bleeding until 3rd day before the 3rd menstrual bleeding (normalized to a standard 56-day period). Treatment period: 2 days before the withdrawal bleeding (WB) of the 1st evaluable treatment cycle until 3rd day before the WB of the cycle after the 2nd evaluable treatment cycle (normalized to a standard 56-day period).
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Baseline period-daily activities impaired | 93.2 | 92.2 |
| Baseline period- leisure activities impaired | 92.3 | 90.0 |
| Treatment period-daily activities impaired | 54.7 | 60.0 |
| Treatment period- leisure activities impaired | 52.6 | 61.3 |
Participants were asked to express the degree of their satisfaction with study treatment.
| Percentage of participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Missing | 0.9 | 1.3 |
| Very satisfied | 53.4 | 50.4 |
| Saatisfied | 32.1 | 30.0 |
| Neither satisfied nor dissatisfied | 7.3 | 8.3 |
| Dissatisfied | 2.1 | 3.5 |
| Very dissatisfied | 0.4 | 0.4 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Days With Bleeding or Spotting | 20.0 ± 8.8 | 23.6 ± 9.7 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Episodes | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Episodes With Bleeding or Spotting | 3.9 ± 1.0 | 4.1 ± 0.8 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Mean Length of Bleeding or Spotting Episodes | 5.17 ± 2.26 | 5.83 ± 2.35 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Maximum Length of Bleeding or Spotting Episodes | 7.1 ± 3.8 | 8.4 ± 5.6 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Difference in Duration Between Longest and Shortest Bleeding or Spotting Episode | 3.6 ± 3.6 | 4.6 ± 5.6 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Days With Spotting-only | 7.3 ± 6.9 | 7.6 ± 7.5 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Episodes | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Episodes With Spotting-only | 0.5 ± 0.8 | 0.4 ± 0.7 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Mean Length of Spotting Only Episodes | 3.29 ± 2.39 | 3.26 ± 2.79 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Maximum Length of Spotting Only Episodes | 3.9 ± 3.1 | 3.6 ± 3.0 |
Bleeding/spotting episodes (day\[s\] with bleeding/spotting preceded and followed by at least 2 bleeding/spotting-free days) were described using the reference period (RP) method (length of RP: 90 days) recommended by the World Health Organization. 1st RP started on the 1st day of study medication. The total number of days during bleeding or spotting episodes was counted. Spotting = less than associated with normal menstruation relative to the subject's experience with no need for sanitary protection (except for panty liners). Bleeding = any bleeding of greater intensity than spotting.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Difference in Duration Between Longest and Shortest Spotting Only Episode | 1.2 ± 2.5 | 0.7 ± 1.5 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Percentage of Participants With Withdrawal Bleeding at Cycle 1 | 91.2 | 93.2 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Percentage of Participants With Withdrawal Bleeding at Cycle 3 | 68.1 | 79.3 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Length of Withdrawal Bleeding Episodes at Cycle 1 | 5.2 ± 2.7 | 5.4 ± 2.4 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Length of Withdrawal Bleeding Episodes at Cycle 3 | 4.5 ± 1.7 | 5.2 ± 2.0 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1 | 3.7 ± 1.0 | 4.0 ± 0.9 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity was defined as: 1 = none, 2 = spotting, 3 = light, 4 = normal, 5 = heavy.
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3 | 3.7 ± 0.8 | 4.1 ± 0.8 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Onset of Withdrawal Bleeding Episodes at Cycle 1 | 4.8 ± 7.0 | 4.9 ± 5.9 |
Withdrawal bleeding was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Onset of Withdrawal Bleeding Episodes at Cycle 3 | 3.1 ± 3.7 | 4.3 ± 4.4 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Percentage of Participants With Intracyclic Bleeding at Cycle 1 | 19.0 | 16.7 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Percentage of Participants With Intracyclic Bleeding at Cycle 3 | 10.8 | 11.6 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Episodes | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Intracyclic Bleeding Episodes at Cycle 1 | 0.2 ± 0.5 | 0.2 ± 0.4 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Episodes | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Intracyclic Bleeding Episodes at Cycle 3 | 0.1 ± 0.3 | 0.1 ± 0.4 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Maximum Length of Intracyclic Bleeding Episodes at Cycle 1 | 6.0 ± 5.4 | 6.2 ± 5.7 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Maximum Length of Intracyclic Bleeding Episodes at Cycle 3 | 5.5 ± 4.7 | 4.9 ± 4.1 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Intracyclic Bleeding Days at Cycle 1 | 1.2 ± 3.5 | 1.0 ± 3.3 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. The total number of days during intracyclic bleeding episodes was counted.
| Days | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Number of Intracyclic Bleeding Days at Cycle 3 | 0.6 ± 2.3 | 0.6 ± 2.1 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.
| Percentage of participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Spotting | 53.5 | 62.2 |
| Light | 30.2 | 10.8 |
| Normal | 9.3 | 13.5 |
| Heavy | 7.0 | 13.5 |
Intracyclic bleeding episodes were any bleeding episodes not qualifying as withdrawal bleeding. The latter was defined as the first bleeding episode after complete or partial progestogen withdrawal (i.e. the first episode starting after the last day of progestogen intake). If a bleeding episode was ongoing on the last day of progestogen intake and the following day, this episode was regarded as the withdrawal bleeding episode, as long as it had started not more than 4 days before the progestogen withdrawal. Intensity could be described as spotting, light, normal or heavy.
| Percentage of participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Spotting | 45.5 | 30.4 |
| Light | 27.3 | 21.7 |
| Normal | 13.6 | 30.4 |
| Heavy | 13.6 | 17.4 |
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Missing | 0.4 | 0.0 |
| Never | 38.0 | 40.4 |
| 4 working hours | 16.2 | 16.1 |
| 1 working day | 26.5 | 29.6 |
| >= 2 working days | 18.8 | 13.9 |
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Missing | 0.0 | 0.0 |
| Never | 47.9 | 51.7 |
| 4 working hours | 13.2 | 11.7 |
| 1 working day | 20.9 | 23.9 |
| >= 2 working days | 17.9 | 12.2 |
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Missing | 0.0 | 0.0 |
| Never | 78.6 | 72.6 |
| 4 working hours | 8.5 | 6.5 |
| 1 working day | 6.4 | 8.7 |
| >= 2 working days | 2.1 | 4.3 |
The investigator was asked to interview the participant and record the number of missed hours/days from work due to dysmenorrheic pain in the previous menstrual cycle.
| Percentage of Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Missing | 0.4 | 0.0 |
| Never | 85.9 | 85.2 |
| 4 working hours | 5.6 | 2.6 |
| 1 working day | 3.0 | 4.8 |
| >= 2 working days | 1.7 | 1.7 |
The participants were asked to complete a resource use questionnaire indicating their own costs of physiotherapy per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Physiotherapy Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
The participants were asked to complete a resource use questionnaire indicating their own costs of pain medication per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Pain Medication Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 5.46 (0.00 to 30.00) | 5.04 (0.00 to 27.49) |
The participants were asked to complete a resource use questionnaire indicating their own costs of vitamins per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Vitamins Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 65.45) | 0.00 (0.00 to 65.45) |
The participants were asked to complete a resource use questionnaire indicating their own costs of massages per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Massages Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 60.00) | 0.00 (0.00 to 295.98) |
The participants were asked to complete a resource use questionnaire indicating their own costs of acupuncture per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Acupuncture Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 150.00) | 0.00 (0.00 to 74.00) |
The participants were asked to complete a resource use questionnaire indicating their own costs of medical counseling per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Medical Counseling Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 271.68) | 0.00 (0.00 to 98.17) |
The participants were asked to complete a resource use questionnaire indicating their own costs of alternative medicine per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Alternative Medicine Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 196.34) | 0.00 (0.00 to 110.00) |
The participants were asked to complete a resource use questionnaire indicating their own costs of herbs/teas per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Own Costs of Herbs/Teas Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 30.00) | 0.00 (0.00 to 10.00) |
The participants were asked to complete a resource use questionnaire indicating their other own costs per treatment of dysmenorrheic pain. Costs were converted to U.S. dollars.
| Dollars | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Other Own Costs Per Treatment Converted to U.S. Dollars as Measured by Resource Use Questionnaire | 0.00 (0.00 to 15.00) | 0.00 (0.00 to 42.00) |
The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Investigators were asked to rate the participants' improvement during the course of the study.
| Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Missing | 0 | 0 |
| Not assessed | 1 | 1 |
| Very much improved | 63 | 42 |
| Much improved | 87 | 84 |
| Minimally improved | 49 | 54 |
| No change | 17 | 23 |
| Minimally worse | 6 | 3 |
| Much worse | 0 | 6 |
The Clinical Global Impression Scale (CGI) is a widely used rating scale/assessment instrument in psychopharmacology research in general, and in studies on women's health in particular. Participants were asked to rate their improvement during the course of the study.
| Participants | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Missing | 1 | 0 |
| Not assessed | 1 | 1 |
| Very much improved | 60 | 46 |
| Much improved | 91 | 75 |
| Minimally improved | 47 | 57 |
| No change | 18 | 24 |
| Minimally worse | 5 | 4 |
| Much worse | 0 | 3 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 90.2 ± 16.7 | 89.6 ± 17.5 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Physical Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 93.7 ± 14.2 | 92.5 ± 15.0 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 78.85 ± 18.99 | 77.35 ± 20.56 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Social Functioning as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 85.95 ± 19.09 | 84.79 ± 17.36 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 73.6 ± 15.6 | 72.6 ± 16.3 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Mental Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 77.3 ± 14.9 | 76.4 ± 14.7 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 62.6 ± 18.0 | 62.2 ± 18.2 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Vitality as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 68.2 ± 17.0 | 67.2 ± 16.8 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| General Health as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 75.8 ± 17.5 | 72.7 ± 16.9 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| General Health as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 77.2 ± 17.9 | 76.5 ± 16.6 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 77.8 ± 33.6 | 79.4 ± 32.7 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Role Physical as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 89.6 ± 23.0 | 87.9 ± 25.9 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 81.91 ± 31.50 | 79.18 ± 34.74 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Role Emotional as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 88.64 ± 26.36 | 83.87 ± 30.28 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Baseline Cycle | 50.7 ± 24.4 | 51.8 ± 23.0 |
The standard questionnaire SF-36v1, a general health status measure used to evaluate patient populations and to compare health status across different populations, was completed by participants as a self-administered native language version. Percentages of absolute scores were calculated such that 0 represents the lowest possible score (worst outcome) and 100 the highest possible score (best outcome)
| Scores on a scale | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Bodily Pain as Measured by General Health and Well-being Questionnaire SF-36 at Final Examination | 77.0 ± 21.5 | 74.0 ± 22.1 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | — | 2/234 (0.9%) | 131/234 (56%) |
| Ethinyl Estradiol, Levonorgestrel (Miranova) | — | 2/230 (0.9%) | 122/230 (53%) |
| Event | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| Animal biteInjury, poisoning and procedural complications | 0/234 | 1/230 |
| DepressionPsychiatric disorders | 0/234 | 1/230 |
| Helminthic infectionInfections and infestations | 1/234 | 0/230 |
| Ovarian torsionReproductive system and breast disorders | 1/234 | 0/230 |
| Event | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) |
|---|---|---|
| DysmenorrhoeaReproductive system and breast disorders | 87/234 | 82/230 |
| HeadacheNervous system disorders | 32/234 | 34/230 |
| MetrorrhagiaReproductive system and breast disorders | 18/234 | 13/230 |
| Tension headacheNervous system disorders | 14/234 | 9/230 |
| Cervical dysplasiaReproductive system and breast disorders | 7/234 | 9/230 |
| Cervix inflammationReproductive system and breast disorders | 9/234 | 4/230 |
| Upper respiratory tract infectionInfections and infestations | 4/234 | 7/230 |
| InflammationGeneral disorders | 7/234 | 3/230 |
| NauseaGastrointestinal disorders | 2/234 | 5/230 |
| InfluenzaInfections and infestations | 2/234 | 5/230 |
| Age, Continuous(Years) | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) | Total |
|---|---|---|---|
| Mean | 28.0 ± 7.9 | 27.6 ± 8.0 | 27.8 ± 7.9 |
| Age, Customized(Participants) | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) | Total |
|---|---|---|---|
| less than 18 years of age | 11 | 13 | 24 |
| 18 years of age or older | 223 | 217 | 440 |
| Sex: Female, Male(Participants) | Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Ethinyl Estradiol, Levonorgestrel (Miranova) | Total |
|---|---|---|---|
| Female | 234 | 230 | 464 |
| Male | 0 | 0 | 0 |
The record gives a start of Apr 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Dienogest